MENU
+Compare
ROIV
Stock ticker: NASDAQ
AS OF
Nov 13, 04:59 PM (EDT)
Price
$20.56
Change
-$0.76 (-3.56%)
Capitalization
14.83B

ROIV Roivant Sciences Ltd Forecast, Technical & Fundamental Analysis

Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients... Show more

ROIV
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
a Summary for ROIV with price predictions
Nov 12, 2025

ROIV in +2.92% Uptrend, advancing for three consecutive days on November 10, 2025

Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where ROIV advanced for three days, in of 262 cases, the price rose further within the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Moving Average Convergence Divergence (MACD) for ROIV just turned positive on October 16, 2025. Looking at past instances where ROIV's MACD turned positive, the stock continued to rise in of 54 cases over the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 188 cases where ROIV Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 20 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

ROIV broke above its upper Bollinger Band on October 20, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. ROIV’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.399) is normal, around the industry mean (24.439). P/E Ratio (1.966) is within average values for comparable stocks, (63.753). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.001). Dividend Yield (0.000) settles around the average of (0.046) among similar stocks. P/S Ratio (714.286) is also within normal values, averaging (322.723).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ROIV’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

View a ticker or compare two or three
ROIV
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published Earnings

ROIV is expected to report earnings to rise 89.82% to -32 cents per share on February 16

Roivant Sciences Ltd ROIV Stock Earnings Reports
Q4'25
Est.
$-0.32
Q3'25
Beat
by $0.15
Q2'25
Missed
by $0.08
Q1'25
Missed
by $0.03
Q4'24
Beat
by $0.48
The last earnings report on November 10 showed earnings per share of -17 cents, beating the estimate of -31 cents. With 3.46M shares outstanding, the current market capitalization sits at 14.83B.
A.I. Advisor
published General Information

General Information

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
50 Broadway
Phone
+44 2074003347
Employees
904
Web
N/A
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
GDXU197.0418.53
+10.38%
MicroSectors™ Gold Miners 3X Lvrgd ETN
JETU24.611.09
+4.64%
MAX Airlines 3X Leveraged ETN
CIL53.180.43
+0.81%
VictoryShares International Vol Wtd ETF
GAUG38.87-0.04
-0.11%
FT Vest U.S. Eq Mod Buffr ETF - Aug
QHY46.46-0.09
-0.19%
WisdomTree US Hi Yld Corp Bd

ROIV and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, ROIV has been loosely correlated with IMVT. These tickers have moved in lockstep 60% of the time. This A.I.-generated data suggests there is some statistical probability that if ROIV jumps, then IMVT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ROIV
1D Price
Change %
ROIV100%
+2.01%
IMVT - ROIV
60%
Loosely correlated
+2.40%
RVMD - ROIV
52%
Loosely correlated
+2.73%
ACLX - ROIV
50%
Loosely correlated
-0.09%
XENE - ROIV
50%
Loosely correlated
-0.60%
IRON - ROIV
49%
Loosely correlated
-0.06%
More